# A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

Source: https://onco.cc/trials/nct07585266/  
OnCo record `nct07585266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Velzatinib in gastrointestinal stromal tumour, now recruiting.

## Summary

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (StrateGIST Frontline) is a phase 3 interventional study registered as NCT07585266, led by GlaxoSmithKline, and recruiting on the registry. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 800 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2032-08-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07585266
- Phase: 3
- Setting: A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
- Sponsor: GlaxoSmithKline
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT07585266: https://clinicaltrials.gov/study/NCT07585266

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- drugs: [Velzatinib](https://onco.cc/drugs/velzatinib/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07585266.json